SECsense Logo

Intellia Therapeutics 8-K Report: Key Updates & Insights for Investors

$NTLA
Form 8-K
Filed on: 2025-01-10
Source
Intellia Therapeutics 8-K Report: Key Updates & Insights for Investors

Based on the provided section of the financial report, here are the key pieces of information and insights:

  1. Entity Information:
  • Company Name: Intellia Therapeutics, Inc.
  • CIK Number: 0001652130
  • State of Incorporation: Delaware (DE)
  • SEC File Number: 001-37766
  • EIN: 36-4785571
  • Headquarters Address: 40 Erie Street, Suite 130, Cambridge, MA 02139
  • Contact Number: (857) 285-6200
  1. Filing Details:
  • Filing Type: 8-K (Report of unscheduled material events or corporate changes)
  • Filing Date: January 9, 2025
  • Period Covered: January 9, 2025
  1. Stock Information:
  • Common Stock: Par value of $0.0001
  • Ticker Symbol: NTLA
  • Exchange: NASDAQ
  1. Regulatory Context:
  • This is an 8-K filing, which typically indicates that the company is reporting significant events that shareholders should be aware of, such as acquisitions, financial results, or changes in management.

Insights:

  • The report indicates a recent significant event or update from Intellia Therapeutics that investors and stakeholders should review.
  • The information can be useful for identifying the company's current status and any potential implications for investment or regulatory compliance.
  • The company's presence in the biotechnology sector, as suggested by its name, may prompt interest in its developments, especially in the context of ongoing innovations in gene editing and therapies.

This summary encapsulates the essential details and context surrounding the filing, which is crucial for stakeholders monitoring the company’s performance and compliance.